Brent Alan Del Monte is named as a lobbyist on federal disclosure filings for 41 clients through Bgr Government Affairs. The most recent filing naming them posted in October 2026. Issues reported include Health Issues, Pharmacy, Tobacco and Medicare/Medicaid.
Filers must list covered executive or legislative branch positions held. As filed:
| Client | Registrant | Latest | Issues |
|---|---|---|---|
| BREAKTHROUGH T1D (F/K/A JDRF) | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| VAXCYTE, INC. | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| NYU LANGONE HEALTH | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| ACADEMY OF NUTRITION AND DIETETICS | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| PTC THERAPEUTICS | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| AKEBIA THERAPEUTICS, INC. | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| ESSILORLUXOTTICA (FKA ESSILOR OF AMERICA, INC.) | BGR GOVERNMENT AFFAIRS | Q3 2026 | Government Issues |
| BAYER CORPORATION | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| AMERICAN SOCIETY OF GENE AND CELL THERAPY | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| WALGREEN CO. | BGR GOVERNMENT AFFAIRS | Q3 2026 | Pharmacy |
| EDWARDS LIFESCIENCES LLC | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| CENTENE CORPORATION | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| NEUROCRINE BIOSCIENCES, INC. | BGR GOVERNMENT AFFAIRS | Q3 2026 | Pharmacy |
| PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | BGR GOVERNMENT AFFAIRS | Q3 2026 | Pharmacy |
| WAYSTAR | BGR GOVERNMENT AFFAIRS | Q3 2026 | Science/Technology, Health Issues |
| BIOMARIN PHARMACEUTICAL INC. | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| ALKERMES, INC. | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| NATIONAL ASSOCIATION OF VISION CARE PLANS | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| NOVARTIS | BGR GOVERNMENT AFFAIRS | Q3 2026 | Medicare/Medicaid, Health Issues |
| REGENERON PHARMACEUTICALS, INC. | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| PFIZER, INC | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| AMGEN INC. | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | BGR GOVERNMENT AFFAIRS | Q3 2026 | Pharmacy |
| GLAXOSMITHKLINE, INC | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| ORCA BIO | BGR GOVERNMENT AFFAIRS | Q3 2026 | Medical/Disease Research/Clinical Labs |
| WELBEHEALTH | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| IOWA PRIMARY CARE ASSOCIATION (NATIONAL PRIMARY CARE ASSOCIATION HUB) | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| ALLIANCE FOR REGENERATIVE MEDICINE | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| FAIRMOUNT FUNDS MANAGEMENT LLC | BGR GOVERNMENT AFFAIRS | Q3 2026 | Health Issues |
| AMEDISYS, INC. | BGR GOVERNMENT AFFAIRS | Q2 2026 | Health Issues |
| RAI SERVICES COMPANY | BGR GOVERNMENT AFFAIRS | Q2 2026 | Tobacco |
| TRANSMEDICS | BGR GOVERNMENT AFFAIRS | Q1 2026 | Health Issues |
| LOCKTON MANAGEMENT, LLC | BGR GOVERNMENT AFFAIRS | Q3 2025 | Health Issues |
| ABIOMED INC | BGR GOVERNMENT AFFAIRS | Q3 2025 | Health Issues |
| GLOBAL KRATOM COALITION | BGR GOVERNMENT AFFAIRS | Q3 2025 | Health Issues |
| STRYKER CORPORATION | BGR GOVERNMENT AFFAIRS | Q2 2025 | Health Issues |
| BIOMERIEUX, INC. | BGR GOVERNMENT AFFAIRS | Q1 2025 | Health Issues |
| EVERYONE MEDICINES | BGR GOVERNMENT AFFAIRS | Q1 2025 | Health Issues |
| ALG SENIOR LLC | BGR GOVERNMENT AFFAIRS | Q1 2025 | Small Business, Housing |
| Year | Clients | Registrants |
|---|---|---|
| 2026 | 34 | 1 |
| 2025 | 39 | 1 |
| Year | Items | Total |
|---|---|---|
| 2026 | 23 | $32K |
Pay is not disclosed for individual lobbyists. Filings do not confirm that records with the same name are one person, so this page may combine people who share the name Brent Alan Del Monte. See the Capitol Clarity rankings and method.